|
業務類別
|
Biotechnology |
|
業務概覽
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs. |
| 公司地址
| Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP |
| 電話號碼
| +31 202406000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.uniqure.com |
| 員工數量
| 221 |
| Dr. Walid Abi-Saab, M.D. |
Chief Medical Officer |
美元 583.80K |
27/04/2026 |
| Mr. Christian Klemt |
Principal Accounting Officer and Chief Financial Officer |
美元 539.22K |
27/04/2026 |
| Mr. Matthew C. Kapusta |
Chief Executive Officer and Director |
美元 676.17K |
27/04/2026 |
| Dr. Jeannette Potts, J.D.,PhD |
Chief Legal and Compliance Officer |
美元 495.01K |
27/04/2026 |
| Ms. Kylie OKeefe |
Chief Customer and Strategy Officer |
-- |
27/04/2026 |
|
|
| Mr. Jack L. Kaye |
Independent Director |
27/04/2026 |
| Dr. Robert Gut, M.D.,PhD |
Independent Director |
27/04/2026 |
| Dr. Jeremy P. Springhorn, PhD |
Independent Director |
27/04/2026 |
| Mr. Madhavan Balachandran |
Independent Director |
27/04/2026 |
| Mr. David D. Meek |
Chairman of the Board |
27/04/2026 |
| Mr. Matthew C. Kapusta |
Chief Executive Officer and Director |
27/04/2026 |
| Ms. Rachelle S. Jacques |
Independent Director |
27/04/2026 |
| Dr. Leonard E. Post, PhD |
Independent Director |
27/04/2026 |
|
|
|
|
